<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    AVEO Pharmaceuticals, Inc.

    AVEO Pharmaceuticals, Inc.

    AVEO Pharmaceuticals, Inc. is a biopharmaceutical company seeking to advance targe...

    AVEO Pharmaceuticals, Inc. is a biopharmaceutic...

    Filing Type:    PU
    Ritter Pharmaceuticals, Inc.

    Ritter Pharmaceuticals, Inc.

    Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the...

    Ritter Pharmaceuticals, Inc. develops novel the...

    Filing Type:    PU
    Cidara Therapeutics, Inc.

    Cidara Therapeutics, Inc.

    Cidara is a clinical-stage biotechnology company focused on the discovery, develop...

    Cidara is a clinical-stage biotechnology compan...

    Filing Type:    PU
    Hoya Corp.

    Hoya Corp.

    Founded in 1941 in Tokyo, Japan, Hoya is a global med-tech company, and a leading ...

    Founded in 1941 in Tokyo, Japan, Hoya is a glob...

    Filing Type:    PU
    Medivie USA Inc

    Medivie USA Inc

    Medivie Therapeutic is an Israeli public company, which developed Laboraide – a ...

    Medivie Therapeutic is an Israeli public compan...

    Filing Type:    RA
    Bio-Path Holdings, Inc.

    Bio-Path Holdings, Inc.

    Bio-Path is a biotechnology company developing targeted therapies for acute myeloi...

    Bio-Path is a biotechnology company developing ...

    Filing Type:    PU
    Compugen Ltd.

    Compugen Ltd.

    Compugen is a drug discovery company with a unique, broadly applicable, predictive...

    Compugen is a drug discovery company with a uni...

    Filing Type:    PU
    OncoSec Medical Incorporated

    OncoSec Medical Incorporated

    OncoSec Medical Incorporated is a clinical-stage biotechnology company focused on ...

    OncoSec Medical Incorporated is a clinical-stag...

    Filing Type:    PU
    Inovio Pharmaceuticals, Inc.

    Inovio Pharmaceuticals, Inc.

    Inovio is bringing IMMUNO-INGENUITY™ to life and is reshaping the future of trea...

    Inovio is bringing IMMUNO-INGENUITY™ to life ...

    Filing Type:    PU
    Oncolytics Biotech Inc.

    Oncolytics Biotech Inc.

    Oncolytics is focused on obtaining regulatory approval for pelareorep for metastat...

    Oncolytics is focused on obtaining regulatory a...

    Filing Type:    PU
    Gritstone Oncology, Inc.

    Gritstone Oncology, Inc.

    Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight mu...

    Gritstone Oncology is developing tumor-specific...

    Filing Type:    PU
    Corvus Pharmaceuticals, Inc.

    Corvus Pharmaceuticals, Inc.

    Corvus Pharmaceuticals is a clinical science-driven biopharmaceutical company. We ...

    Corvus Pharmaceuticals is a clinical science-dr...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.